Effect of Obesity, Dyslipidemia, and Diabetes on Trastuzumab-related Cardiotoxicity in Breast Cancer | Zendy

Pauline K. Kosalka | Zendy; Christopher Johnson | Zendy; Michèle Turek | Zendy; Jeffrey Sulpher | Zendy; Angeline Law | Zendy; J. Botros | Zendy; Susan Dent | Zendy; O. Aseyev | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Obesity, Dyslipidemia, and Diabetes on Trastuzumab-related Cardiotoxicity in Breast Cancer

Author(s) -

Pauline K. Kosalka,

Christopher Johnson,

Michèle Turek,

Jeffrey Sulpher,

Angeline Law,

J. Botros,

Susan Dent,

O. Aseyev

Publication year - 2019

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.26.4823

Subject(s) - medicine , trastuzumab , dyslipidemia , cardiotoxicity , breast cancer , population , diabetes mellitus , cancer , obesity , oncology , chemotherapy , endocrinology , environmental health

Clinical trials have demonstrated an increased risk of cardiotoxicity in patients with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and obesity are known risk factors for cardiovascular disease. Studies have yielded conflicting results about whether those factors increase the risk of cardiotoxicity in patients with bca receiving trastuzumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research